{"id":"aapa","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of genital yeast infections"}]},"_chembl":{"chemblId":"CHEMBL94895","moleculeType":"Small molecule","molecularWeight":"502.29"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"AAPA works by inhibiting the SGLT2 receptor in the kidneys, reducing glucose reabsorption and lowering blood glucose levels. This mechanism is particularly effective in treating type 2 diabetes.","oneSentence":"AAPA is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:58:24.678Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT00857675","phase":"PHASE3","title":"A Efficacy and Safety Study of Adefovir Dipivoxil to Treat Chinese Patients With HBeAg+ve Chronic Hepatitis B","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2002-12","conditions":"Chronic Hepatitis B","enrollment":480}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":207,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"AAPA","genericName":"AAPA","companyName":"GlaxoSmithKline","companyId":"glaxosmithkline","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AAPA is a small molecule that targets the SGLT2 receptor. Used for Treatment of type 2 diabetes.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}